Impact of the SGLT2-inhibitor Empagliflozin on inflammatory biomarkers in acute myocardial infarction-a post-hoc analysis of the EMMY trial

被引：0
|
作者：
Benedikt, M. [1 ]
Kolesnik, E. [1 ]
Wallner, M. [1 ]
Zirlik, A. [1 ]
Sourij, H. [2 ]
Tripolt, N. [2 ]
Aziz, F. [2 ]
Vonbank, A. [3 ]
Purkarthofer, D. [4 ]
Wester, S. [5 ]
Kopp, K. [6 ]
Nahler, A. [7 ]
von Lewinski, D. [1 ]
机构：
[1] Med Univ Graz, Kardiol, Graz, Austria
[2] Med Univ Graz, Endokrinol, Graz, Austria
[3] VIVIT LKH Feldkirch, Feldkirch, Feldkirch, Austria
[4] LKH II, Kardiol, Graz, Austria
[5] LKH Klagenfurt, Kardiol, Klagenfurt, Austria
[6] Paracelsus Univ Salzburg, Salzburg, Austria
[7] Kepleruniv Linz, Kardiol, Linz, Austria
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 2023年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1-3
引用
收藏
页码：S359 / S360
页数：2
相关论文
共 50 条
  • [41] Effect of empagliflozin versus placebo on body composition in patients with acute myocardial infarction and type 2 diabetes mellitus: subgroup analysis of the EMBODY trial
    Hoshika, Y.
    Kubota, Y.
    Mozawa, K.
    Yodogawa, K.
    Iwasaki, Y.
    Yamamoto, T.
    Takano, H.
    Tsukada, Y.
    Asai, K.
    Miyauchi, Y.
    Kodani, E.
    Maruyama, M.
    Tanabe, J.
    Shimizu, W.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3065 - 3065
  • [42] Blood pressure reduction with empagliflozin in Japanese patients with type 2 diabetes and cardiovascular diseases: a post-hoc sub-analysis of the placebo-controlled randomized EMBLEM trial
    Tanaka, Atsushi
    Shimabukuro, Michio
    Teragawa, Hiroki
    Yoshida, Hisako
    Okada, Yosuke
    Takamura, Toshinari
    Taguchi, Isao
    Toyoda, Shigeru
    Tomiyama, Hirofumi
    Ueda, Shinichiro
    Higashi, Yukihito
    Node, Koichi
    HYPERTENSION RESEARCH, 2024, 47 (09) : 2295 - 2302
  • [43] Impact of telemedical management on hospitalization and mortality in heart failure patients with diabetes: a post-hoc subgroup analysis of the TIM-HF2 trial
    Koehler, Friedrich
    Koehler, Johanna
    Bramlage, Peter
    Vettorazzi, Eik
    Wegscheider, Karl
    Lezius, Susanne
    Spethmann, Sebastian
    Iakoubov, Roman
    Vijayan, Anjaly
    Winkler, Sebastian
    Melzer, Christoph
    Schuett, Katharina
    Dessapt-Baradez, Cecile
    Paar, W. Dieter
    Koehler, Kerstin
    Mueller-Wieland, Dirk
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [44] Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial
    Bogoviku, J.
    Haertel, F.
    Westphal, J. G.
    Moebius-Winkler, S.
    Schulze, P. C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 404 - 405
  • [45] ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis
    Orban, Martin
    Limbourg, Tobias
    Neumann, Franz-Josef
    Ferenc, Miroslaw
    Olbrich, Hans-Georg
    Richardt, Gert
    Hennersdorf, Marcus
    Empen, Klaus
    Fuernau, Georg
    Desch, Steffen
    Eitel, Ingo
    Hambrecht, Rainer
    Poess, Janine
    Schneider, Steffen
    Schuler, Gerhard
    Werdan, Karl
    Zeymer, Uwe
    Thiele, Holger
    Hausleiter, Joerg
    EUROINTERVENTION, 2016, 12 (11) : E1395 - E1403
  • [46] Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial
    Hoshika, Yu
    Kubota, Yoshiaki
    Mozawa, Kosuke
    Tara, Shuhei
    Tokita, Yukichi
    Yodogawa, Kenji
    Iwasaki, Yu-Ki
    Yamamoto, Takeshi
    Takano, Hitoshi
    Tsukada, Yayoi
    Asai, Kuniya
    Miyamoto, Masaaki
    Miyauchi, Yasushi
    Kodani, Eitaro
    Maruyama, Mitsunori
    Tanabe, Jun
    Shimizu, Wataru
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (01) : 56 - 64
  • [47] THE IMPACT OF FRACTIONAL FLOW RESERVE FOLLOWING ADMINISTRATION OF POTENT P2Y12 INHIBITORS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND MULTIVESSEL DISEASE: POST HOC ANALYSIS OF THE FRAME-AMI TRIAL
    Lim, Sungmin
    Lee, Sang Yeub
    Kim, Chan Joon
    Bae, Jang-Whan
    Chang, Kiyuk
    Choi, Ki Hong
    Kim, Hyun Kuk
    Lee, Joo Myung
    Hahn, Joo-Yong
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1090 - 1090
  • [48] Effect of Empagliflozin versus Placebo on Plasma Volume Status in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the Embody Trial
    Hoshika, Yu
    Kubota, Yoshiaki
    Mozawa, Kosuke
    Tara, Shuhei
    Tokita, Yukichi
    Yodogawa, Kenji
    Iwasaki, Yuki
    Yamamoto, Takeshi
    Takano, Hitoshi
    Tsukada, Yayoi
    Asai, Kuniya
    Miyamoto, Masaaki
    Miyauchi, Yasushi
    Kodani, Eitaro
    Maruyama, Mitsunori
    Tanabe, Jun
    Shimizu, Wataru
    CIRCULATION, 2020, 142
  • [49] P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial
    Roh, Ji Woong
    Hahn, Joo-Yong
    Oh, Ju-Hyeon
    Chun, Woo Jung
    Park, Yong Hwan
    Jang, Woo Jin
    Im, Eul-Soon
    Jeong, Jin-Ok
    Cho, Byung Ryul
    Oh, Seok Kyu
    Yun, Kyeong Ho
    Cho, Deok-Kyu
    Lee, Jong-Young
    Koh, Young-Youp
    Bae, Jang-Whan
    Choi, Jae Woong
    Lee, Wang Soo
    Yoon, Hyuck Jun
    Lee, Seung Uk
    Cho, Jang Hyun
    Choi, Woong Gil
    Rha, Seung-Woon
    Kim, Hee-Yeol
    Lee, Joo Myung
    Park, Taek Kyu
    Yang, Jeong Hoon
    Choi, Jin-Ho
    Choi, Seung-Hyuck
    Lee, Sang Hoon
    Gwon, Hyeon-Cheol
    Kim, Dong-Bin
    Bin Song, Young
    CARDIOLOGY JOURNAL, 2021, 28 (06) : 855 - 863
  • [50] Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
    Sen, Taha
    Koshino, Akihiko
    Neal, Bruce
    Bijlsma, Maarten J.
    Arnott, Clare
    Li, Jingwei
    Hansen, Michael K.
    Ix, Joachim H.
    Heerspink, Hiddo J. L.
    DIABETES OBESITY & METABOLISM, 2022, 24 (10): : 1950 - 1956
12345